Recent analyses predict that the platelet-rich plasma (PRP) segment alone will grow from around USD 730 million in 2025 to over USD 1.3 billion by 2030, reflecting an average annual growth rate of more than 12%.

This acceleration is linked to improvements in plasma separation, growth factor concentration, and point-of-care preparation – technologies that are making procedures faster, safer, and more consistent across surgical, orthopaedic, and aesthetic settings.  

Industry leaders including Zimmer Biomet, Arthrex, Terumo BCT, Grifols, and Baxter International are expanding clinical validation programmes and global distribution to capture a share of this high-growth sector, as regenerative therapies become an increasingly integral part of mainstream practice.